Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Change in Accured Expenses (2016 - 2025)

International Stem Cell (ISCO) has disclosed Change in Accured Expenses for 16 consecutive years, with -$199000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 109.47% to -$199000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$23000.0, a 169.7% decrease, with the full-year FY2024 number at $42000.0, up 282.61% from a year prior.
  • Change in Accured Expenses was -$199000.0 for Q3 2025 at International Stem Cell, down from $43000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $174000.0 in Q1 2021 to a low of -$237000.0 in Q3 2021.
  • A 5-year average of $3421.1 and a median of $33000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 656.25% in 2021, then plummeted 5450.0% in 2023.
  • International Stem Cell's Change in Accured Expenses stood at $121000.0 in 2021, then crashed by 72.73% to $33000.0 in 2022, then soared by 30.3% to $43000.0 in 2023, then rose by 20.93% to $52000.0 in 2024, then tumbled by 482.69% to -$199000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Change in Accured Expenses are -$199000.0 (Q3 2025), $43000.0 (Q2 2025), and $81000.0 (Q1 2025).